Functionalized MoS 2 -nanoparticles for transdermal drug delivery of atenolol
Molybdenum disulfide (MoS ) has excellent photothermal conversion abilities, an ultra-high specific surface area, and has been extensively explored for use in biomedicine. However, the high toxicity associated with MoS has limited its biological applications for photothermal therapy and drug deliver...
Gespeichert in:
Veröffentlicht in: | Drug delivery 2020-12, Vol.27 (1), p.909-916 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Molybdenum disulfide (MoS
) has excellent photothermal conversion abilities, an ultra-high specific surface area, and has been extensively explored for use in biomedicine. However, the high toxicity associated with MoS
has limited its biological applications for
photothermal therapy and drug delivery systems. Herein, we have developed cationic hydroxyethyl cellulose (JR400) surface-modified MoS
nanoparticles (NPs) that are responsive to near-infrared (NIR) laser irradiation as a transdermal drug delivery system (TDDS). Herein, we confirmed the preparation of hexagonal phase MoS
with robust surface modification with JR400. The flower-like morphology of the NPs had an average diameter of 355 ± 69.3 nm limiting the absorption of the NPs through the stratum corneum. With the ability to efficiently load 90.4 ± 0.3% of the model drug atenolol (ATE), where 1 g of JR400-MoS
NPs was able to load 3.6 g ATE, we assayed the controlled release capacity
skin penetration studies. These JR400-MoS
NPs showed further enhancement under NIR stimulation, with a 2.3-fold increase in ATE skin penetration. Furthermore, we verified
that these JR400-MoS
NPs do not cause skin irritation suggesting that they are promising new TDDS candidates for small molecule drugs. |
---|---|
ISSN: | 1071-7544 1521-0464 |
DOI: | 10.1080/10717544.2020.1778815 |